Voloridge Investment Management
EIDX

Voloridge Investment Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Voloridge Investment Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,741
Closed -$2.33M – 1763
2020
Q4 		$2.33M Buy
+17,741
New +$1.57M 0.02% 678
2020
Q1 		– Sell
-3,872
Closed -$222K – 1524
2019
Q4 		$222K Buy
+3,872
New +$192K ﹤0.01% 983

Voloridge Investment Management's EIDX Position: Q1 2021 in Review

Voloridge Investment Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 17,741 shares — an estimated $2.33M sold.

Voloridge Investment Management first reported a position in EIDX in Q4 2019 and held it in 2 quarters. The position peaked at $2.33M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Voloridge Investment Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Voloridge Investment Management sold 17,741 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.33M.
  • Voloridge Investment Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Voloridge Investment Management's Eidos Therapeutics, Inc. Common Stock position peaked at $2.33M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Voloridge Investment Management's 13F filing for Q1 2021, filed 17 May 2021.